Drug
400 Microgrammes Gsk961081
400 Microgrammes Gsk961081: highest development phase Phase 2, developed by Theravance Biopharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Theravance Biopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| 400 microgrammes GSK961081 NCT00674817 | Phase 2 | Pulmonary Disease, Chronic Obstructive |
Latest
No recent events.
Follow 400 Microgrammes Gsk961081 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.